Free tool
FAERS Monitor: Gleostine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017588 or its brand name (Gleostine, Lomustine). Reports on generic versions are filed under their own applications.
Reports
2,597
Serious
1,796
69% of reports
Hospitalization
553
Death reported
587
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death273
- off label use254
- nausea232
- fatigue219
- thrombocytopenia187
- disease progression144
- neutropenia134
- drug ineffective126
- platelet count decreased114
- vomiting110
- seizure92
- headache87
- product use in unapproved indication77
- constipation73
- malignant neoplasm progression73
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 11 |
| 2009 | 21 |
| 2010 | 26 |
| 2011 | 16 |
| 2012 | 54 |
| 2013 | 30 |
| 2014 | 54 |
| 2015 | 73 |
| 2016 | 94 |
| 2017 | 247 |
| 2018 | 298 |
| 2019 | 291 |
| 2020 | 232 |
| 2021 | 238 |
| 2022 | 222 |
| 2023 | 219 |
| 2024 | 156 |
| 2025 | 152 |
| 2026 | 134 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,562 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| thrombocytopeniaSignal | 187 | 13.6 | 11.8 | 2,172 |
| disease progressionSignal | 144 | 9.9 | 8.4 | 1,144 |
| platelet count decreasedSignal | 114 | 8.7 | 7.2 | 769 |
| neutropeniaSignal | 134 | 8.0 | 6.8 | 817 |
| seizureSignal | 92 | 6.5 | 5.3 | 421 |
| malignant neoplasm progressionSignal | 73 | 5.8 | 4.6 | 285 |
| constipationSignal | 73 | 2.7 | 2.2 | 78 |
| deathSignal | 273 | 2.6 | 2.3 | 271 |
| product use in unapproved indicationSignal | 77 | 2.5 | 2.0 | 70 |
| nauseaSignal | 232 | 2.4 | 2.1 | 190 |
| off label useSignal | 254 | 2.3 | 2.1 | 204 |
| fatigueSignal | 219 | 2.3 | 2.0 | 162 |
| vomiting | 110 | 1.9 | 1.6 | 47 |
| headache | 87 | 1.1 | 0.9 | 1 |
| drug ineffective | 126 | 0.8 | 0.7 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.